To evaluate this idea, we chose SSR128129E, which is an allosteric inhibitor of FGF receptor signaling at nanomolar concentrations.26 We examined whether API5 is required for susceptibility of cancer cells to SSR128129E. The gene discussed is API5; the disease is cancer.